Wall Street Zen upgrades Kodiak Sciences stock to Sell

Published on 10/08/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Loss reached USD 65.6 million in second quarter of 2026. Kodiak Sciences stock costs EUR 81.04 on October 8, 2026 after EUR 81.66, minus 0.76 percent.

KOD, US50015M1099, Illustration mit AI erstellt.

Wall Street Zen upgraded Kodiak Sciences stock from strong sell to sell on October 4, 2026, as MarketBeat reported. The rating change contrasts with six Buy ratings, one Hold rating and one Sell rating cited in the same report.

Three milestones reshape Kodiak

On August 13, 2026, Kodiak reported a USD 65.6 million net loss for the second quarter of 2026, compared with USD 54.3 million in the second quarter of 2025, according to Trivano. The company also held USD 125.9 million in cash and cash equivalents at June 30, 2026, while research and development spending reached USD 56.1 million.

On September 28, 2026, Kodiak said Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK study. The release said 54 percent of Zenkuda patients reached six-month dosing at year one, while the cataract rate was 0.5 percent for Zenkuda versus 0.9 percent for aflibercept, according to Kodiak Sciences.

What does the trial change?

The DAYBREAK result shifts the discussion from clinical proof toward regulatory execution. Kodiak plans to submit Zenkuda data in the fourth quarter of 2026 from five positive Phase 3 studies, but the planned filing remains subject to regulatory review and approval.

The financial profile remains a counterweight to the clinical progress. Research and development expenses rose from USD 42.8 million in the second quarter of 2025 to USD 56.1 million in the second quarter of 2026, while the quarterly net loss widened by USD 11.3 million over the same comparison.

Dates investors can track

The next explicitly dated reporting event is November 12, 2026, listed as Kodiak's next earnings date by Yahoo Finance. Kodiak also plans to report topline data from the Phase 3 PEAK study in December 2026, according to its September 28 release.

Stock remains below the prior close

Kodiak Sciences stock was trading at EUR 81.04 at Lang & Schwarz on October 8, 2026 at 1:15 p.m. CEST, minus 0.76 percent versus the EUR 81.66 prior close of October 7, 2026. The primary Nasdaq quote was USD 91.08 on October 7, 2026, and the 52-week range was USD 2.81 to USD 104.00; market capitalization was USD 5.7 billion as of that date.

The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.